# Onc.ai

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/onc-ai

- Industry: Healthcare
- Headquarters: San Carlos, US
- Website: www.onc.ai
- Total disclosed funding: $31M
- Latest round: Series A (Jan 5, 2023)
- Investors on record: 7

## About

Onc.ai, Inc., located in San Carlos, US, specializes in AI-driven technology that enhances cancer treatment decision-making through advanced analytics and precision oncology solutions.Founded in 2020, Onc.ai, Inc. focuses on leveraging AI to improve outcomes in oncology through deep learning models. The company completed its Series A funding round in January 2023, raising USD 25.00 mn from investors including MassMutual Ventures and Action Potential Venture Capital, while maintaining a current valuation of USD 64.31 mn. The leadership includes CEO Akshay Nanduri, one of the founders alongside Petr Jordan and Salmaan Ahmed, who have a history in the healthcare technology sector.Onc.ai offers sophisticated AI-powered technology aimed at enhancing decision-making in cancer treatment, particularly through precision oncology. Its primary offerings utilize extensive real-world datasets, including diagnostic imaging and genomic data, to develop deep learning models that predict clinical outcomes in metastatic lung cancer. Onc.ai's solutions are currently undergoing the FDA approval process, with a focus on regulated markets in the US, while also eyeing future expansion opportunities.Onc.ai generates revenue through partnerships with healthcare providers and pharmaceutical companies, engaging in B2B transactions. The company’s offerings, which are in the investigational phase, provide insights that assist oncologists and pharmaceutical developers in making informed cancer treatment decisions. This business model likely involves subscription agreements or partnerships, allowing clients to access Onc.ai's predictive analytics tools, thereby integrating its technologies into clinical workflows.In January 2023, Onc.ai raised USD 25.00 mn in Series A funding aimed at developing digital clinical management solutions specifically for immuno-oncology therapies. The company plans to leverage this funding to enhance its product offerings and expand its market reach, with a strategic focus on entering additional healthcare markets and geographic regions as it grows.

## Funding rounds

- Series A, Jan 5, 2023, $25M — BlueCross BlueShield Venture Partners, Action Potential Venture Capital, MassMutual Ventures, Accomplice, Digitalis Ventures, KdT Ventures, Life Extension Ventures
- Seed, Nov 17, 2020, $6M — BlueCross BlueShield Venture Partners, Accomplice, Digitalis Ventures, KdT Ventures

## Investors

- BlueCross BlueShield Venture Partners (https://capitalatlas.ai/funds/bluecross-blueshield-venture-partners) — Seed, Series A
- Accomplice (https://capitalatlas.ai/funds/accomplice) — Seed, Series A
- Digitalis Ventures (https://capitalatlas.ai/funds/digitalis-ventures) — Seed, Series A
- KdT Ventures (https://capitalatlas.ai/funds/kdt-ventures) — Seed, Series A
- Action Potential Venture Capital (https://capitalatlas.ai/funds/action-potential-venture-capital) — Series A
- MassMutual Ventures (https://capitalatlas.ai/funds/massmutual-ventures) — Series A
- Life Extension Ventures (https://capitalatlas.ai/funds/life-extension-ventures) — Series A